Niagen Bioscience Debuts Clinician-Directed Platform
References: businesswire
Niagen Bioscience has launched a clinician-directed telehealth platform called Niagen Plus. This innovation offers eligible patients in the United States access to a prescription-only at-home injection kit featuring pharmaceutical-grade Niagen — a patented form of nicotinamide riboside chloride designed to support cellular and tissue health by boosting NAD+ levels, a vital coenzyme that declines with age and lifestyle stressors.
Niagen Bioscience’s clinician-directed telehealth platform guides patients through an online medical intake and consultation with a licensed provider, and if prescribed, a complete kit manufactured under current Good Manufacturing Practice standards is dispensed by a licensed pharmacy and shipped directly to the patient's door. This kit contains a sterile 500 milligram vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, mixing supplies, alcohol prep pads, and step-by-step instructions.
The at-home subcutaneous administration eliminates the need for in-person clinic visits or pharmacy trips, with clinical safety trials reporting that the injection was generally well-tolerated with no significant adverse effects at 50 and 100 milligram dosages.
Image Credit: Niagen Bioscience
Niagen Bioscience’s clinician-directed telehealth platform guides patients through an online medical intake and consultation with a licensed provider, and if prescribed, a complete kit manufactured under current Good Manufacturing Practice standards is dispensed by a licensed pharmacy and shipped directly to the patient's door. This kit contains a sterile 500 milligram vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, mixing supplies, alcohol prep pads, and step-by-step instructions.
The at-home subcutaneous administration eliminates the need for in-person clinic visits or pharmacy trips, with clinical safety trials reporting that the injection was generally well-tolerated with no significant adverse effects at 50 and 100 milligram dosages.
Image Credit: Niagen Bioscience
Trend Themes
-
Clinician-directed Telehealth — A model that centers licensed providers in remote prescribing workflows creates new pathways for tightly regulated, prescription-only therapies to be delivered and monitored outside traditional clinics.
-
Prescription At-home Injectables — The rise of complete at-home injection kits signals potential to shift routine parenteral therapies from infusion centers to patient homes with integrated safety and supply-chain controls.
-
NAD+ Therapeutics Expansion — Growing clinical interest in NAD+ precursors for age-related and metabolic health opens avenues for novel therapeutic formulations and targeted longevity interventions backed by biomarker-driven patient selection.
Industry Implications
-
Telemedicine Platforms — Platforms that embed licensed-provider consults, digital intake, and compliance workflows are positioned to enable regulated drug delivery and post-prescription monitoring at scale.
-
Pharmaceutical Compounding and Distribution — Specialized pharmacies and fulfillment services capable of GMP-compliant kit assembly and cold-chain logistics could redefine last-mile delivery of prescription biologics and parenteral products.
-
Anti-aging Biotech — Companies focused on cellular metabolism and longevity biomarkers stand to benefit from clinician-guided deployment of targeted NAD+ boosters as part of personalized wellness regimens.
9.2
Score
Popularity
Activity
Freshness
